Kuros Biosciences AG

Kuros Biosciences Expands into Extremities Markets

Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024

Kuros Biosciences Reports First Half of 2024 Results

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales

Annual General Meeting of Kuros Biosciences approves all resolutions